Featured Research

from universities, journals, and other organizations

Severe combined immune deficiency: Early detection and transplantation provide best outcomes

Date:
July 30, 2014
Source:
Dana-Farber Cancer Institute
Summary:
Children born with severe combined immune deficiency (SCID) have the best chance of survival if they undergo a hematopoietic stem cell transplant as soon after birth as possible, according to a detailed analysis of 10 years of outcome data. These findings, the researchers say, argue for expanding newborn screening for SCID, which leaves affected infants so vulnerable to infection that most die by their first birthday.

Children born with severe combined immune deficiency (SCID) have the best chance of survival if they undergo a hematopoietic stem cell transplant as soon after birth as possible, according to a detailed analysis of 10 years of outcome data by researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center. These findings, the researchers say, argue for expanding newborn screening for SCID, a disorder that leaves affected infants so vulnerable to infection that most die within the first year of life if untreated.

Related Articles


The study, recently published in the New England Journal of Medicine, analyzes data on 240 children with SCID transplanted at 25 centers across North America between Jan. 1, 2000 and Dec. 31, 2009, the decade before the U.S. Department of Health and Human Services recommended newborn screening for SCID in 2010. Currently, 21 states and the District of Columbia -- together home to about two-thirds of all babies born in the United States -- screen newborns for SCID. Another nine states are expected to implement newborn screening by the end of 2014.

In addition to patient age, the analysis finds that infection status at the time of transplant and donor source had the strongest impact on transplant outcomes (i.e., five-year survival and successful immune system reconstitution).

"Survival is much, much better if infants undergo transplant before they turn 3½ months old and before they contract any SCID-related infections," says study first author Sung-Yun Pai, MD, of Dana-Farber/Boston Children's. "The best way to identify patients that early when there is no family history of SCID is through newborn screening."

Data gained from newborn screening suggest that SCID, while still rare, is twice as common as once thought. "Some children who succumbed to unexplained infections probably suffered from SCID," Pai notes. The disorder is now estimated to occur in one of every 50,000 births, up from earlier estimates of one in 100,000 births.

"Time is not the ally of children with SCID," says Luigi Notarangelo, MD, of Boston Children's Hospital, one of the study's senior authors, who was among those who lobbied successfully to establish SCID newborn screening in Massachusetts in 2009. "Because they do not have a functional immune system, the longer the wait before a transplant the greater the risk they will contract a potentially devastating infection."

The new study was conducted under the auspices of the Primary Immune Deficiency Treatment Consortium, a North American collaborative supported by the National Institutes of Health. It looked at the effect on outcomes of patient age, infection status, donor source, and the use of chemotherapy to condition patients prior to transplant.

Children who underwent transplant before 3.5 months of age had excellent survival, regardless of donor source or infection status, as did patients transplanted with the stem cells of a matched sibling donor, long recognized as the gold standard of transplant. Children outside that age group also had very good survival regardless of donor source -- sibling, parent or unrelated donor -- as long as the patient did not have an active infection at the time of transplant. The effect on survival of donor type and pre-transplant conditioning was only discernible in actively infected patients.

  • Overall, 74 percent of the 240 patients studied survived at least five years.
  • Among patients transplanted younger than 3.5 months, 94 percent survived.
  • Virtually all (97 percent) of patients who received stem cells from a matched sibling donor survived.
  • At 50 percent, survival was lowest among patients who were older than 3.5 months and had active infections at the time of transplant. Actively infected infants who did not have a matched sibling donor and who received immunosuppressive or chemotherapy prior to transplant had particularly poor survival (39-53%).
  • Among patients who never had an infection, 90 percent survived, as did 82 percent of patients whose infection had resolved before transplant.

While survivors who received chemotherapy conditioning have stronger immune systems after transplant, further research is needed, Pai says, to determine whether the late effects of chemotherapy or the vulnerabilities of a weaker immune system pose the greater long-term risk.

"This study accomplishes several things," Pai notes. "First, it creates a baseline with which to compare patient outcomes since the advent of newborn screening for SCID. Second, it provides guidance for clinicians regarding the use of chemotherapy conditioning before transplantation. Third, it highlights the relative impacts of infection status and patient age on transplant success.

"Lastly," she adds, "it establishes the importance of early detection and transplantation, which points to the benefit of expanding newborn screening for SCID as broadly as possible."


Story Source:

The above story is based on materials provided by Dana-Farber Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Sung-Yun Pai, Brent R. Logan, Linda M. Griffith, Rebecca H. Buckley, Roberta E. Parrott, Christopher C. Dvorak, Neena Kapoor, Imelda C. Hanson, Alexandra H. Filipovich, Soma Jyonouchi, Kathleen E. Sullivan, Trudy N. Small, Lauri Burroughs, Suzanne Skoda-Smith, Ann E. Haight, Audrey Grizzle, Michael A. Pulsipher, Ka Wah Chan, Ramsay L. Fuleihan, Elie Haddad, Brett Loechelt, Victor M. Aquino, Alfred Gillio, Jeffrey Davis, Alan Knutsen, Angela R. Smith, Theodore B. Moore, Marlis L. Schroeder, Frederick D. Goldman, James A. Connelly, Matthew H. Porteus, Qun Xiang, William T. Shearer, Thomas A. Fleisher, Donald B. Kohn, Jennifer M. Puck, Luigi D. Notarangelo, Morton J. Cowan, Richard J. O'Reilly. Transplantation Outcomes for Severe Combined Immunodeficiency, 2000–2009. New England Journal of Medicine, 2014; 371 (5): 434 DOI: 10.1056/NEJMoa1401177

Cite This Page:

Dana-Farber Cancer Institute. "Severe combined immune deficiency: Early detection and transplantation provide best outcomes." ScienceDaily. ScienceDaily, 30 July 2014. <www.sciencedaily.com/releases/2014/07/140730173143.htm>.
Dana-Farber Cancer Institute. (2014, July 30). Severe combined immune deficiency: Early detection and transplantation provide best outcomes. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2014/07/140730173143.htm
Dana-Farber Cancer Institute. "Severe combined immune deficiency: Early detection and transplantation provide best outcomes." ScienceDaily. www.sciencedaily.com/releases/2014/07/140730173143.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins